occurring gonadotropin-releasing hormone (GnRH) – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:52 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg occurring gonadotropin-releasing hormone (GnRH) – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Goserelin Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-goserelin-market-2021-2025/ Tue, 08 Jun 2021 05:57:03 +0000 https://www.cri-report.com/?post_type=product&p=11769 In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the annual growth rate of Goserelin’s sales value dropped to 8.76% in 2020.

The post Investigation Report on China’s Goserelin Market 2021-2025 first appeared on CRI Report.

]]> Goserelin is a synthetic analogue of a naturally occurring gonadotropin-releasing hormone (GnRH). Goserelin is developed by AstraZeneca, is mainly used to treat advanced breast and prostate cancer. In 1996, 3.6 mg of Goserelin was approved to enter the Chinese market, and in 2012, 10.8 mg of Goserelin was approved to enter the Chinese market and has been included in China’s Class B medical insurance catalog. By the end of 2020, the only manufacturer in China is AstraZeneca UK Ltd.

According to CRI’s market research, the sales value of Goserelin in the Chinese market has increased year by year since 2016-2020, with the CAGR from 2016 to 2019 is around 18%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the annual growth rate of Goserelin’s sales value dropped to 8.76% in 2020. However, the sales value of Goserelin in the Chinese market reached CNY990 million in 2020 and the CAGR of the sales value of Goserelin in the Chinese market is 15.94% from 2016 to 2020.

CRI predicts that with the increase in the number of patients with indications, the sales volume of Goserelin will steadily increase from 2021 to 2025. In 2020, the number of new breast cancers worldwide reached 2.26 million, and the number of prostate cancers was 1.41 million, both of which were on the rise. Therefore, the sales volume of Goserelin for the treatment of breast cancer and prostate cancer increased with the increase in the number of patients diagnosed with breast cancer and prostate cancer, and its sales also increased. China has approved Luye Pharmaceuticals to conduct generic drug clinical trials and has successfully conducted Phase III clinical trials at the end of 2020. It is expected that the generic drug will be launched in the next five years. As a result, the price of Goserelin will continue to fall, sales and sales volume will also have certain upside potential. In addition, the effective alleviation of COVID-19 will also cause a recovery growth in the sales of Goserelin.

Topics Covered:
-The impact of COVID-19 on China’s Goserelin market
– Sales value of China’s Goserelin 2016-2020
– Competitive landscape of China’s Goserelin market
– Prices of Goserelin in China
– Prices of Goserelin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Goserelin market
– Prospect of China’s Goserelin market from 2021 to 2025

The post Investigation Report on China’s Goserelin Market 2021-2025 first appeared on CRI Report.

]]>